Curasight announces broadening and extension of patent protection for uTRACE®
- Issuance of new patent related to uTRACE® will broaden protection
- Patent coverage has been extended by 751 days and now expires 2035
- Strengthened patent protection significantly enhances the potential financial value of uTRACE®
Copenhagen, Denmark, 01 October 2025 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today the issuance of US patent 12,409,240 B2 which expands the protection of the company’s uPAR diagnostic platform, uTRACE. The patent term has also been extended by 751 days (more than 2 years) so that it now expires in 2035. This significantly extends the patent protection for uTRACE, enhancing the platform’s potential value across current and future cancer programs.
“We are committed to ensuring robust patent protection for our technology as we advance our theranostic approach, combining our diagnostic platform uTRACE® and our therapeutic platform uTREAT® to improve cancer diagnosis and treatment. This new US patent for uTRACE not only reinforces the protection of our proprietary technology and extends the platform’s patent life, but also adds important value to our ongoing prostate cancer program with Curium – as well as to any potential future development of uTRACE in additional cancer cancer indications”, said Curasight CEO Ulrich Krasilnikoff.
About Curasight’s theranostic platform
Curasight’s radiopharmaceutical theranostic platform builds on uPAR-targeting peptides labelled either with radioisotopes suitable for imaging, uTRACE®, or labelled with radioisotopes suitable for radioligand therapy, uTREAT®. The target, uPAR, is expressed in the majority of solid tumors and is a marker of cancer aggressiveness.